Literature DB >> 23795223

A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.

Amy J Davidoff, Ilene H Zuckerman, Naimish Pandya, Franklin Hendrick, Xuehua Ke, Arti Hurria, Stuart M Lichtman, Arif Hussain, Jonathan P Weiner, Martin J Edelman.   

Abstract

OBJECTIVES: To develop and provide initial validation for amultivariate, claims-based prediction model for disability status (DS), a proxymeasure of performance status (PS), among older adults. The model was designed to augment information on health status at the point of cancer diagnosis in studies using insurance claims to examine cancer treatment and outcomes.
MATERIALS AND METHODS: We used data from the 2001–2005 Medicare Current Beneficiary Survey (MCBS), with observations randomly split into estimation and validation subsamples. We developed an algorithm linking self-reported functional status measures to a DS scale, a proxy for the Eastern Cooperative Oncology Group (ECOG) PS scale. The DS measure was dichotomized to focus on good [ECOG 0–2] versus poor [ECOG 3–4] PS. We identified potential claims-based predictors, and estimated multivariate logistic regression models, with poor DS as the dependent measure, using a stepwise approach to select the optimal model. Construct validity was tested by determining whether the predicted DS measure generated by the model was a significant predictor of survival within a validation sample from the MCBS. RESULTS AND
CONCLUSION: One-tenth of the beneficiaries met the definition for poor DS. The base model yielded high sensitivity (0.79) and specificity (0.92); positive predictive value=48.3% and negative predictive value=97.8%, c-statistic=0.92 and good model calibration. Adjusted poor claims-based DS was associated with an increased hazard of death (HR=3.53, 95% CI 3.18, 3.92). The ability to assess DS should improve covariate control and reduce indication bias in observational studies of cancer treatment and outcomes based on insurance claims.

Entities:  

Mesh:

Year:  2013        PMID: 23795223      PMCID: PMC3685201          DOI: 10.1016/j.jgo.2012.12.005

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  24 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

Authors:  Lazzaro Repetto; Lucia Fratino; Riccardo A Audisio; Antonella Venturino; Walter Gianni; Marina Vercelli; Stefano Parodi; Denise Dal Lago; Flora Gioia; Silvio Monfardini; Matti S Aapro; Diego Serraino; Vittorina Zagonel
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.

Authors:  Amy J Davidoff; James F Gardner; Brian Seal; Martin J Edelman
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

Review 6.  Influence of age and comorbidities on the chemotherapeutic management of lung cancer.

Authors:  K M Deppermann
Journal:  Lung Cancer       Date:  2001-09       Impact factor: 5.705

7.  Potential for cancer related health services research using a linked Medicare-tumor registry database.

Authors:  A L Potosky; G F Riley; J D Lubitz; R M Mentnech; L G Kessler
Journal:  Med Care       Date:  1993-08       Impact factor: 2.983

8.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

9.  A profile of the Medicare Current Beneficiary Survey.

Authors:  G S Adler
Journal:  Health Care Financ Rev       Date:  1994

Review 10.  Use of geriatric assessment for older adults in the oncology setting: a systematic review.

Authors:  M T E Puts; J Hardt; J Monette; V Girre; E Springall; S M H Alibhai
Journal:  J Natl Cancer Inst       Date:  2012-07-31       Impact factor: 13.506

View more
  61 in total

1.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

2.  Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults: Validation of an Existing Medicare Claims-based Algorithm.

Authors:  Carmen C Cuthbertson; Anna Kucharska-Newton; Keturah R Faurot; Til Stürmer; Michele Jonsson Funk; Priya Palta; B Gwen Windham; Sydney Thai; Jennifer L Lund
Journal:  Epidemiology       Date:  2018-07       Impact factor: 4.822

3.  Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Authors:  Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff
Journal:  Cancer       Date:  2018-09-14       Impact factor: 6.860

4.  Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.

Authors:  Kenneth L Kehl; Christopher S Lathan; Bruce E Johnson; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

5.  Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study.

Authors:  Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2019-12-26

6.  Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer.

Authors:  James B Yu; Pamela R Soulos; Laura D Cramer; Roy H Decker; Anthony W Kim; Cary P Gross
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

7.  Using claims data to predict dependency in activities of daily living as a proxy for frailty.

Authors:  Keturah R Faurot; Michele Jonsson Funk; Virginia Pate; M Alan Brookhart; Amanda Patrick; Laura C Hanson; Wendy Camelo Castillo; Til Stürmer
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-10-21       Impact factor: 2.890

8.  Development and validation of a 5-year mortality prediction model using regularized regression and Medicare data.

Authors:  Jennifer L Lund; Tzy-Mey Kuo; M Alan Brookhart; Anne-Marie Meyer; Alexandra F Dalton; Christine E Kistler; Stephanie B Wheeler; Carmen L Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-03-19       Impact factor: 2.890

9.  Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.

Authors:  Janaki A Deepak; Xinyi Ng; Josephine Feliciano; Li Mao; Amy J Davidoff
Journal:  Ann Am Thorac Soc       Date:  2015-05

10.  Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Authors:  Franklin Hendrick; Amy J Davidoff; Amer M Zeidan; Steven D Gore; Maria R Baer
Journal:  Medicare Medicaid Res Rev       Date:  2014-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.